Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI.

Trial Profile

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Sunitinib (Primary) ; Gadopentetic acid
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Jun 2012 Actual patient number is 18 according to ClinicalTrials.gov.
    • 15 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top